Breaking News
Get 50% Off 0
📈 Q2 Earnings Alert! Critical earnings dates you can't miss
See Calendar
Close

Getinge AB ser. B (GETIBs)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
195.30 +7.38    +3.93%
23/07 - Closed. Currency in SEK
Type:  Equity
Market:  Euro Zone
ISIN:  SE0000202624 
  • Volume: 1,032
  • Bid/Ask: 186.20 / 187.65
  • Day's Range: 194.23 - 195.30
Getinge B 195.30 +7.38 +3.93%

Getinge AB ser. B Company Profile

 
Get an in-depth profile of Getinge AB ser. B, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryHealthcare Equipment & Supplies
SectorHealthcare
Employees

11791

Equity Type

ORD

Getinge AB (publ) provides products and solutions for operating rooms, intensive-care units, and sterilization departments in Sweden and internationally. The company operates through Acute Care Therapies, Life Science, and Surgical Workflows segments. It provides extracorporeal membrane oxygenation, mechanical ventilation, advanced patient monitoring, ICU infrastructure equipment, and drainage solutions. In addition, the company offers surgical perfusion, endoscopic vessel harvesting, intra-aortic balloon counterpulsation, vascular and cardiothoracic surgery equipment, peripheral stenting, OEM solutions, and beating heart surgery equipment; and operating room equipment, anesthesia, advanced patient monitoring, and operating room integration solutions. Further, it provides pre-cleaning, cleaning and disinfection, sterilization, consumables, endoscope reprocessing, and sterile supply management solutions; connected medical devices, and patient flow management; and low temperature sterilization, biocontainment in vaccine production, terminal sterilization, sterile isolation technology, cleaning and sterilization, aseptic transfer, and large-scale cultivation. Additionally, the company provides bioreactor preparation solution, bioprocess development and optimization, labware cleaning and sterilization, biocontainment, and vivarium. It offers its products through a network of sales companies, as well as through agents and distributors in the Americas, Europe, the Middle East, Africa, and the Asia and Pacific. Getinge AB (publ) was founded in 1904 and is headquartered in Gothenburg, Sweden.

Contact Information

Address Lindholmspiren 7A P.O. Box 8861
Gothenburg, SE-417 56
Sweden
Phone 46 1 03 35 00 00
Fax 46 1 03 35 56 40

Top Executives

Name Age Since Title
Åke Larsson 56 2022 Alternate Director
Carl Bennet 74 1989 Non-Independent Vice Chairman
Johan Bygge 69 2007 Independent Director
Cecilia Daun Wennborg 62 2010 Independent Director
Mattias Perjos 53 2017 CEO, President & Director
Ake Larsson 59 2022 Employee Representative Director
Dan Frohm 44 2017 Non-Independent Director
Kristian Samuelsson 48 2021 Independent Director
Fredrik Brattborn 49 2020 Employee Representative Director
Johan Malmquist 64 1997 Independent Chairman
Ida Ekman 40 2022 Deputy Director
Pontus Kall 34 2022 Deputy Director
Ulrika Dellby 59 2025 Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

GETIBs Comments

Write your thoughts about Getinge AB ser. B
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email